Skin n Skin Co. Ltd (159910) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Skin n Skin Co. Ltd stock KRW 717, price KRW 3,400, that is 78.9% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 2,480 KRW – 23,750 KRW · fair‑value band 473.03 KRW – 895.89 KRW · the 3,400 KRW price screens above the 716.71 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Skin n Skin Co. in your weekly email
Every Wednesday you see whether Skin n Skin Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EcoGlow Co., Ltd. manufactures and distributes cosmetics and merchandise. It offers skin care products under the t-Timing brand; and beauty tea cafe under the a;t fox brand name. The company was formerly known as Skin n Skin Co., Ltd. and changed its name to EcoGlow Co., Ltd. in May 2025.
Show moreShow less
EcoGlow Co., Ltd. was founded in 2006 and is headquartered in Paju-Si, South Korea.
Stock analysis
Skin n Skin Co. Ltd (159910) currently trades at 3,400 KRW, while our model-based Fair Value estimate is 716.71 KRW, 79% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 473.03 KRW (bear) to 895.89 KRW (bull), the price of 3,400 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Skin n Skin Co. Ltd reported revenue of 9.9B KRW in FY2025 versus 27.6B KRW in FY2021, a compound −22.6%/yr. Reported net income was −5.7B KRW in FY2025.
Key figures
Market cap 35.4B KRW (≈ $26.2M) Micro · P/S ratio 3.56 · EPS (TTM) −280.80 KRW · Net margin −57.2% · Return on equity −17.3% · Return on assets (EBIT) −16.9% (5-year average) · Operating margin −430% · Revenue (TTM) 8.5B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 26% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −79%, 159910 screens richer than that median.
Fair Value models
Bear473.03 KRWFair Value 716.71 KRWBull895.89 KRW
Price 3,400 KRW · Downside -78.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−31.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.7%
Start year 2020 (pandemic). Over 10 years: −6.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−48.0% (2020) → −39.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−78.1% · Bottom 25%
Profitability
Return on assets−15.4% · Bottom 25%
Net margin (12 months)−51.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−86.1% · Bottom 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B1.73× · Pricier than median
P/S (12 months)4.02× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 36
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 31
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Skin n Skin Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/159910
Frequently asked questions
Is Skin n Skin Co. Ltd (159910) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 716.71 KRW versus a price of 3,400 KRW, about 79% lower (overvalued).
What is the fair value of 159910?
Our model-based fair value for Skin n Skin Co. Ltd is 716.71 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 3,400 KRW.
What is the quality score of 159910?
Skin n Skin Co. Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Skin n Skin Co. Ltd (159910)?
Our model-based price target is the fair value of 716.71 KRW (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 473.03 KRW, optimistic scenario 895.89 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Skin n Skin Co. Ltd stock forecast for 2026?
Our models put fair value at 716.71 KRW, about 79% lower versus a price of 3,400 KRW (overvalued). Cautious scenario 473.03 KRW, optimistic scenario 895.89 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Skin n Skin Co. Ltd (159910)?
Skin n Skin Co. Ltd reported trailing-twelve-month revenue of about 8.5B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Skin n Skin Co. Ltd (159910)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Skin n Skin Co. Ltd it is 716.71 KRW per share (as of Nov 3, 2026), against a price of 3,400 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Skin n Skin Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 159910 trades above its calculated fair value: price 3,400 KRW, fair value 716.71 KRW, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 159910?
No. The price is what the market pays today (3,400 KRW); the fair value is what the company's own numbers justify (716.71 KRW). For Skin n Skin Co. Ltd the two are 2,683 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Skin n Skin Co. Ltd worth?
The market values Skin n Skin Co. Ltd at about 35.4B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 3,400 KRW; our models calculate a fair value of 716.71 KRW per share.
What do the bullish and bearish scenarios say about 159910?
Our models span a range for Skin n Skin Co. Ltd: cautious scenario 473.03 KRW, base 716.71 KRW, optimistic 895.89 KRW per share (as of Nov 3, 2026, price 3,400 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Skin n Skin Co. Ltd (159910)?
Balance-sheet figures for Skin n Skin Co. Ltd (as of Nov 3, 2026): return on equity −17.3%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 159910 from its 52-week high?
Skin n Skin Co. Ltd trades at 3,400 KRW, about 26% below its 52-week high of 4,585 KRW and 37% above the low of 2,480 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 716.71 KRW is for.
Which stocks are comparable to Skin n Skin Co. Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Skin n Skin Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 3,400 KRW, calculated fair value 716.71 KRW (−79%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 159910 calculated?
We run Skin n Skin Co. Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 716.71 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Skin n Skin Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Skin n Skin Co. Ltd (159910)?
The closing price on Nov 9, 2026 was 3,400 KRW. Our model-based fair value is 716.71 KRW, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Skin n Skin Co. Ltd right now?
The price sits above even our optimistic bull case (895.89 KRW). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (473.03 KRW to 895.89 KRW) leaves room in how you read the outcome.
Key figures of Skin n Skin Co. Ltd
How large is the market capitalisation of Skin n Skin Co. Ltd (159910)?
The market capitalisation of Skin n Skin Co. Ltd is 35.4B KRW (≈ $26.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Skin n Skin Co. Ltd (159910)?
The price-to-sales ratio of Skin n Skin Co. Ltd is 3.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Skin n Skin Co. Ltd (159910)?
Earnings per share at Skin n Skin Co. Ltd are −280.80 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Skin n Skin Co. Ltd (159910)?
The net margin of Skin n Skin Co. Ltd is −57.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Skin n Skin Co. Ltd (159910)?
The return on equity (ROE) of Skin n Skin Co. Ltd is −17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Skin n Skin Co. Ltd (159910)?
On an EBIT basis the return on assets of Skin n Skin Co. Ltd is −16.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Skin n Skin Co. Ltd (159910)?
The operating margin of Skin n Skin Co. Ltd is −430% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Skin n Skin Co. Ltd (159910)?
Revenue at Skin n Skin Co. Ltd is growing −86.1% versus a year earlier (3y avg −9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Skin n Skin Co. Ltd (159910) generate?
The free cash flow of Skin n Skin Co. Ltd is −5.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Skin n Skin Co. Ltd (159910) carry?
The net debt of Skin n Skin Co. Ltd is 592M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Skin n Skin Co. Ltd in the live analysis
One click puts Skin n Skin Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026